Halozyme to Present at Upcoming Investor Conferences
November 27, 2023 at 08:01 am EST
Share
SAN DIEGO, Nov. 27, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that members of the senior leadership team are scheduled to present and host investor meetings at the following investor conferences. Details on the presentations are as follow:
Event:
Presenter:
Format:
Presentation Date:
Location:
Presenter:
Format:
Presentation Date:
Location:
Miami, FL
A live audio webcast of the presentations will be available in the Investor Relations section of the Company's website. Replays of the audio webcasts will be available for 90 days following the conference. About Halozyme
Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. As the innovators of the ENHANZE® technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the delivery of injected drugs and fluids in order to reduce the treatment burden to patients. Having touched more than 700,000 patient lives in post-marketing use in seven commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, AbbVie, Eli Lilly, Bristol Myers Squibb, Alexion, argenx, Horizon Therapeutics, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals. Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The Company has a commercial portfolio of proprietary products including XYOSTED® and TLANDO® and partnered commercial products and ongoing product development programs with several pharmaceutical companies including Teva Pharmaceuticals and Idorsia Pharmaceuticals. Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility. For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter. Contacts:

Halozyme to Present at Upcoming Investor Conferences

News provided by
Share this article
Share toX
SAN DIEGO, Nov. 27, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ("Halozyme") today announced that members of the senior leadership team are scheduled to present and host investor meetings at the following investor conferences. Details on the presentations are as follow:
Event:
Presenter:
Format:
Presentation Date:
Location:
Presenter:
Format:
Presentation Date:
Location:
Miami, FL
A live audio webcast of the presentations will be available in the  Investor Relations section  of the Company's website. Replays of the audio webcasts will be available for 90 days following the conference. About Halozyme
Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. As the innovators of the ENHANZE® technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the delivery of injected drugs and fluids in order to reduce the treatment burden to patients. Having touched more than 700,000 patient lives in post-marketing use in seven commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, AbbVie, Eli Lilly, Bristol Myers Squibb, Alexion, argenx, Horizon Therapeutics, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals. Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The Company has a commercial portfolio of proprietary products including XYOSTED® and TLANDO® and partnered commercial products and ongoing product development programs with several pharmaceutical companies including Teva Pharmaceuticals and Idorsia Pharmaceuticals. Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility. For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter . Contacts:
609-359-3016
Also from this source
Enter Your Email
By signing up you agree to receive content from us. Our newsletters contain tracking pixels to help us deliver unique content based on each subscriber's engagement and interests. For more information on how we will use your data to ensure we send you relevant content please visit our  PRN Consumer Newsletter Privacy Notice . You can withdraw your consent at any time in the footer of every email you'll receive.Mit Ihrer Anmeldung erklären Sie sich damit einverstanden, Inhalte von uns zu erhalten. Unsere Newsletter enthalten Zählpixel, die die Lieferung einzigartiger Inhalte in Bezug auf das Abonnement und die Interessen der einzelnen Abonnenten ermöglichen. Weitere Informationen über die Verwendung Ihrer Daten im Hinblick auf die Zusendung von relevanten Inhalten, finden Sie in unserer  PRN Consumer Newsletter Privacy Notice . Ihre Zustimmung können Sie jederzeit in der Fußzeile jeder erhaltenen E-Mail widerrufen.En vous inscrivant à la newsletter, vous consentez à la réception de contenus de notre part. Notre newsletter contient des pixels espions nous permettant la fourniture à chaque abonné, d’un contenu unique en lien avec ses souscriptions et intérêts. Pour de plus amples informations sur l’utilisation faite de vos données en vue de l’envoi des contenus concernés, nous vous invitons à consulter la politique de confidentialité disponible à partir du lien suivant  PRN Consumer Newsletter Privacy Notice . Vous pouvez à tout moment revenir sur votre consentement par le biais des informations situées au bas de chaque e-mail reçu.Регистрирайки се, Вие се съгласявате да получавате информационно съдържание от нас. Нашите бюлетини съдържат проследяващи пиксели, които ни помагат да предоставяме уникално съдържание въз основа на ангажираността и интересите на всеки абонат. За повече информация относно начина, по който ще използваме Вашите данни, за да гарантираме, че Ви изпращаме подходящо съдържание, моля, направете справка с нашето Уведомление за поверителност на потребителския бюлетин на  PRN . Можете да оттеглите съгласието си по всяко време в долния колонтитул на всеки от имейлите, които ще получите.

08:00 ET
Halozyme to Present at Upcoming Investor Conferences

News provided by
Share this article
VYVGART® SC Now Approved for Subcutaneous Administration, Adding to the Already Approved IV Administration
SAN DIEGO, Nov. 16, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ("Halozyme") today announced that argenx received European Commission (EC) approval of VYVGART® SC (efgartigimod alfa and hyaluronidase-qvfc) co-formulated with ENHANZE® for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. The European approval of VYVGART SC provides the option for patient self-administration. The EC approval is applicable to all 27 European Union Member States plus Iceland, Norway and Liechtenstein. "We are excited that the European approval of VYVGART SC for patients with generalized myasthenia gravis follows closely on the U.S. approval in June of this year, resulting in many new gMG patients having the option to receive their treatment as a 30-90 second subcutaneous administration," said Dr. Helen Torley, president and chief executive officer of Halozyme. VYVGART® SC is a subcutaneous product combination of efgartigimod alfa, a human IgG1 antibody fragment marketed for intravenous use as VYVGART®, and recombinant human hyaluronidase PH20 (rHuPH20), Halozyme's ENHANZE® drug delivery technology to facilitate subcutaneous delivery of biologics. VYVGART® SC was approved by the U.S. Food and Drug Administration in June 2023 and is marketed as VYVGART® Hytrulo. The EC approval follows a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) and is based on positive results from the Phase 3 ADAPT-SC study. ADAPT-SC established the efficacy of VYVGART® SC by demonstrating a reduction in anti-AChR antibody levels comparable to VYVGART® IV in adult gMG patients. About Halozyme
Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. As the innovators of the ENHANZE® technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the delivery of injected drugs and fluids in order to reduce the treatment burden to patients. Having touched more than 700,000 patient lives in post-marketing use in seven commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, AbbVie, Eli Lilly, Bristol Myers Squibb, Alexion, argenx, Horizon Therapeutics, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals. Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The Company has a commercial portfolio of proprietary products including XYOSTED® and TLANDO® and partnered commercial products and ongoing product development programs with several pharmaceutical companies including Teva Pharmaceuticals and Idorsia Pharmaceuticals. Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility. For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter . Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning the possible activity, benefits and attributes of ENHANZE®, the possible method of action of ENHANZE®, its potential application to aid in the dispersion and absorption of other injected therapeutic drugs, and statements concerning certain other potential benefits of ENHANZE® including facilitating more rapid delivery of injectable medications through subcutaneous delivery and potentially lowering the treatment burden for patients and broadening the treatment options for the indication referred to in this press release. These forward-looking statements also include statements regarding the product development efforts of Halozyme's ENHANZE® partners, potential additional data readouts, indications and eligible patients for the ENHANZE® co-formulated treatment referred to in this press release. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including uncertainties concerning whether new ENHANZE® collaborative products are ultimately developed, approved or commercialized or whether additional indications for the ENHANZE® co-formulated treatment referred to in this press release will be approved  for additional indications, unexpected results or delays in development and regulatory review, unexpected regulatory approval requirements, unexpected adverse events or patient outcomes from being treated with the ENHANZE® co-formulated treatment referred to in this press release, and competitive conditions. These and other factors that may result in differences are discussed in greater detail in Halozyme's most recent Annual and Quarterly Reports filed with the Securities and Exchange Commission. Except as required by law, Halozyme undertakes no duty to update forward-looking statements to reflect events after the date of this release. Contacts:

09:00 ET
Halozyme Announces argenx Receives European Commission Approval of VYVGART® SC with ENHANZE® for Generalized Myasthenia...

(marketscreener.com) 

VYVGART® SC Now Approved for Subcutaneous Administration, Adding to the Already Approved IV Administration 
SAN DIEGO, Nov. 16, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc.   today announced that argenx received European Commission  approval of VYVGART® SC  co-formulated with ENHANZE® for the treatment of generalized...https://www.marketscreener.com/quote/stock/HALOZYME-THERAPEUTICS-INC-50245/news/Halozyme-Announces-argenx-Receives-European-Commission-Approval-of-VYVGART-SC-with-ENHANZE-for-Gen-45374351/?utm_medium=RSS&utm_content=20231116

Halozyme Announces argenx Receives European Commission Approval of VYVGART® SC with ENHANZE® for Generalized Myasthenia Gravis

Editor
Among dealmaking news last week, US biotechs Halozyme  Therapeutics and Acumen Pharmaceuticals signed a license  collaboration for the use of Enhanze drug delivery for Acumen’s  Alzheimer’s disease candidate ACU193. On the regulatory front,  the US Food and Drug Administration (FDA) last Wednesday approved  Eli Lilly’s tirzepatide, under the trade name Zepbound, as a  treatment for chronic weight management,…
This article is accessible to registered users, to continue reading please register for free . A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please  login . If your trial has come to an end, you can  subscribe here. • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. • Daily roundup of key events in pharma and biotech. • Monthly in-depth briefings on Boardroom appointments and M&A news. • Choose from a cost-effective annual package or a flexible monthly subscription. If you are already a registered user please login . The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK

The week in pharma: action, reaction and insight – week to November 10, 2023

Acumen Pharmaceuticals is a company focused on the development of targeted treatments for Alzheimer's disease within the pharmaceutical industry. The company's main offerings include therapies that target toxic soluble amyloid-beta oligomers, a primary driver of Alzheimer's-associated neurodegeneration, with the aim of providing disease-modifying benefits and potential symptomatic relief for patients. Acumen primarily serves the healthcare sector, specifically those dealing with neurodegenerative diseases. It was founded in 1996 and is based in Charlottesville, Virginia.

Acumen Pharmaceuticals

SAN DIEGO , Nov. 6 , 2023 / PRNewswire / -- Halozyme Therapeutics , Inc. today announced a global collaboration and non-exclusive license agreement with Acumen Pharmaceuticals that provides Acumen Pharmaceuticals access to Halozyme Therapeutics , Inc. 's ENHANZE drug delivery technology , a proprietary recombinant human hyaluronidase PH20 enzyme for rapid subcutaneous drug delivery , for a single target .

Halozyme and Acumen Pharmaceuticals Enter Global Collaboration and Non-Exclusive License Agreement for the ENHANZE® Technology in Alzheimer's Disease

Chugai Pharmaceutical (TYO: 4519) operates as a research-based pharmaceutical company producing biotechnology products. The company's main offerings include the development and provision of innovative drug candidates, with a particular emphasis on addressing unmet medical needs in areas such as oncology, bone and joint diseases, and renal diseases. It primarily serves the healthcare industry. It was founded in 1925 and is based in Tokyo, Japan.

Chugai Pharmaceutical

Chugai Pharmaceutical represents Halozyme Therapeutics , Inc. 's twelfth global collaboration and license partner for the ENHANZE technology .

08:00 EDT
Halozyme Therapeutics, Inc. and Chugai Pharmaceutical Enter Global Collaboration and License Agreement for ENHANZE® Te...

Chugai Pharmaceutical represents Halozyme 's twelfth global collaboration and license partner for the ENHANZE technology .

Halozyme Therapeutics, Inc. and Chugai Pharmaceutical Enter Global Collaboration and License Agreement for ENHANZE® Technology.

ViiV Healthcare offers products and services to diagnose, prevent and treat disease. Its prescription medicines for use by healthcare professionals are regulated by government agencies in each of the countries in which it does business, such as the Food and Drug Administration in the United States (U.S.) or the Medicines Control Agency in the United Kingdom.

Viiv Healthcare

Bonti

Unattributed VC - II

Halozyme Therapeutics is a biopharmaceutical company that focuses on improving patient experiences and outcomes through innovative drug delivery technologies. The company's main offerings include the development of new drugs and the provision of disruptive solutions such as the ENHANZE® technology, which facilitates the delivery of injected drugs and fluids, potentially reducing treatment time. Halozyme primarily serves the biopharmaceutical industry, partnering with leading companies to develop and commercialize products that improve patient lives. It was founded in 1998 and is based in San Diego, California.

Name	Work History	Title	Status
David A. Ramsay	Bonti	Chief Financial Officer	Current
Subscribe to see more	Subscribe to see more	Subscribe to see more	Subscribe to see more
Subscribe to see more	Subscribe to see more	Subscribe to see more	Subscribe to see more
Subscribe to see more	Subscribe to see more	Subscribe to see more	Subscribe to see more
Subscribe to see more	Subscribe to see more	Subscribe to see more	Subscribe to see more

Name	David A. Ramsay	Subscribe to see more	Subscribe to see more	Subscribe to see more	Subscribe to see more
Work History	Bonti	Subscribe to see more	Subscribe to see more	Subscribe to see more	Subscribe to see more
Title	Chief Financial Officer	Subscribe to see more	Subscribe to see more	Subscribe to see more	Subscribe to see more
Status	Current	Subscribe to see more	Subscribe to see more	Subscribe to see more	Subscribe to see more

Wells Fargo Success Story

Professional Services

Platform Overview

Halozyme Therapeutics

Executives

Halozyme Therapeutics Management Team

10 Team Members